FDA grants fast track status to Heidelberg Pharma’s Amanitin-based ADC candidate for multiple myeloma
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
